60 DEGREES PHARMACEUTICALS, INC.
Income Statement
| Line Item | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $207.9K | $162.1K | $303.4K | $437.6K | $100.9K | $163.6K | $241.6K | $135.3K |
| Cost of Revenue | $151.1K | $85.7K | $120.7K | $537.7K | $50.1K | $73.3K | $118.1K | $111.7K |
| Gross Profit | $56.8K | $76.4K | $182.7K | $-100.1K | $50.9K | $90.3K | $123.6K | $23.6K |
| Gross Margin | 27.3% | 47.1% | 60.2% | -22.9% | 50.4% | 55.2% | 51.1% | 17.4% |
| Operating Expenses | ||||||||
| Research & Development | $598.7K | $281.5K | $693.7K | $809.8K | $231.9K | $370.8K | $614.0K | $940.1K |
| SG&A Expense | $1.7M | $1.9M | $1.4M | $1.5M | $1.6M | $1.7M | $1.6M | $1.2M |
| Operating Income | $-2.3M | $-2.1M | $-1.9M | $-2.3M | $-1.6M | $-1.9M | $-2.1M | $-2.1M |
| Operating Margin | -1,092.4% | -1,292.5% | -631.5% | -531.4% | -1,591.5% | -1,168.4% | -854.7% | -1,566.0% |
| Interest Expense | — | — | — | — | — | — | $-1.4K | $0 |
| Pretax Income | $-2.3M | $-2.1M | $-1.4M | $-2.3M | $-1.7M | $-1.9M | $-2.0M | $-2.2M |
| Income Tax Expense | — | — | $-1.8K | $250 | $1.5K | $63 | $-751 | $250 |
| Net Income | $-2.3M | $-2.1M | $-1.4M | $-2.3M | $-1.7M | $-1.9M | $-2.0M | $-2.2M |
| Net Margin | -1,089.2% | -1,288.9% | -474.2% | -529.3% | -1,717.7% | -1,147.4% | -846.3% | -1,596.4% |
| EPS (Basic) | $-0.90 | $-1.28 | $0.19 | $-0.11 | $-0.84 | $-1.04 | $-8.37 | $-0.78 |
| EPS (Diluted) | $-0.90 | $-1.28 | $0.19 | $-0.11 | $-0.84 | $-1.04 | $-8.66 | $-0.49 |
| Shares Outstanding (Basic) | 2.7M | 1.7M | 670.2K | 22.1M | 2.2M | 1.9M | 682.0K | 2.9M |
| Shares Outstanding (Diluted) | 2.7M | 1.7M | 670.2K | 22.1M | 2.2M | 1.9M | 682.0K | 12.9M |
| Dividends Per Share | — | — | — | — | — | — | — | — |